Kimryn Rathmell, CEO of Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, highlighted the team’s presence at the 25th American Society of Hematology (ASH) Annual Meeting. The James is showcasing over 100 presentations that demonstrate advances in hematology oncology and innovations in blood cancer treatment.
Attendees are encouraged to visit booth 181 to engage with experts and explore the full presentation schedule. Key research areas include developing next-generation CAR T-cell therapies and applying artificial intelligence to improve understanding and treatment of blood cancers.
The team is also leading clinical trials on novel inhibitors, such as next-generation BTK inhibitors, to address treatment resistance in challenging cases. Additionally, they are advancing precision medicine approaches to better assess cancer risk and optimize therapies for aggressive leukemias in vulnerable adult populations.
Leave a Reply